Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1.

In April 2008, Lorus' subsidiary GeneSense Technologies entered into an exclusive multinational license agreement for Virulizin(R) with Zor Pharmaceuticals LLC to further develop and commercialize Virulizin(R) for advanced pancreatic cancer and other therapy areas in North and South America, Europe, and Israel.

Virulizin(R) study leads to new drug candidate IL-17E

The article entitled "Virulizin(R) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors" was published online in the journal Cancer Immunology Immunotherapy and is available through PubMed (http://www.ncbi.nlm.nih.gov/PubMed/).

The study showed that Virulizin(R) treatment stimulates the immune system to produce the cytokine IL-17E, which in turn triggers an anticancer effect through activation and tumor recruitment of eosinophils. This novel aspect of the anticancer mechanism of action for Virulizin(R) adds to previous studies showing that Virulizin(R) activates other cells of the immune system, including macrophages and Natural Killer (NK) cells.

A key finding of this report was that IL-17E itself had significant anticancer activity when used in mouse models of human cancers. Preliminary studies have revealed that IL-17E has potent activity against several human tumor types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Lorus has patent applications pending in major markets, including Canada, Europe and the United St
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014   Propeller Health , the ... the hire of Brad Towle as Senior ... responsible for driving the company,s sales growth, customer acquisition ... healthcare, and specifically his past role in the development ... company at this pivotal time in the industry," said ...
(Date:7/28/2014)... It’s a hard truth: Nearly half of recent veterans who ... are failing to obtain a diploma or certificate within a ... an analysis by The Resume Place , a major ... college majors, which leads to underemployment, unemployment or just plain ... of post-9/11 veterans using GI Bill education benefits ...
(Date:7/28/2014)... BRISBANE, Calif. , July 28, 2014  InterMune, ... it will release its second quarter 2014 financial results ... August 6, 2014. A live conference call and webcast will ... that same day. Interested investors and others ... (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A replay of ...
(Date:7/28/2014)... , July 28, 2014 Research and Markets ... Size Analysis Market 2014-2018" report to their offering. ... size analysis is a technique used to determine the size ... liquid. It is crucial to analyze the size of particles ... particle size analysis is performed to determine the behavior and ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2Global Particle Size Analysis Market 2014-2018 2
... , , MOUNTAIN ... ALXA ) announced that during a special meeting of stockholders held ... Company,s common stock and warrants to purchase shares of the Company,s ... Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, ...
... ... website at www.TrustedLASIKSurgeons.com in order to provide a resource for consumers ... can help them attain better vision. What sets the Trusted LASIK Surgeons ... among the best fo the best in LASIK Laser eye surgery ...
... , AIX-EN-PROVENCE, France, Aug. 25 ... from the FDA for its Aixplorer(TM) ultrasound system and will ... States. Aixplorer is the only commercially available system of ... between conventional longitudinal waves and shear waves in tissue. ...
Cached Biology Technology:Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 2Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 3Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 4LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 2LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 3LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 4LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 5LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 6LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory 7SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4
(Date:7/28/2014)... the University of Arizona has sequenced the complete genome ... scientists, and agriculturalists, understanding of the growing patterns of ... new rice varieties that are better able to cope ... challenges. , The paper, "The genome sequence of African ... domestication," was published online in Nature Genetics ...
(Date:7/28/2014)... at Yale School of Medicine have pinpointed a mechanism in ... levels in the blood, linking it to both type 1 ... July 28 issue of Proceedings of the National Academies ... endopeptidase enzyme located in a part of the hypothalamus ... steps in motion that control glucose levels in the blood," ...
(Date:7/28/2014)... There is no cure for Alzheimer,s disease and other ... step closer to finding treatment. , University of Washington ... stop the harmful changes of the body,s normal proteins ... as Alzheimer,s, Parkinson,s, heart disease, Type 2 diabetes and ... as they shift from their normal state into an ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... today identifies two genetic variants that increase the risk ... provides clues to the origin of this often very ... quality of life of sufferers. Details of ... for Human Genetics and the Nuffield Department of Obstetrics ...
... RIVERSIDE, Calif. Researchers at the University of California, ... inhibit the movement of cancer cells and weaken their ... of prostate cancer to the bone. The research ... Performed in the lab of Manuela Martins-Green ...
... Scientists have sequenced the genome of a major fungal ... that could lead to significant advances in our understanding of ... journal Science , suggests that parasites within the genome ... the plant,s defences. The study could help with ...
Cached Biology News:Genetic variants linked to increased risk of common gynecological disease 2UCR scientists identify pomegranate juice components that could stop cancer from spreading 2Genome of barley disease reveals surprises 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SSA (Sheep serum albumin) lysine through amide bonds. This product is homologous to NP-BSA....
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Biology Products: